Sanofi-Aventis, as reported in the Shanghai Daily, launched its new R&D center in China yesterday. The new center is intended to accelerate development of therapies for disease more prevalent in the region.
The R&D center in China is in addition to R&D operations that Sanofi has started in Russia, South Korea and India. The multi-national drug company states that it expects that up to 33% of its sales income will come from emerging markets in the next few years.
Sanofi has a stated goal of becoming first multi-national to bring "home grown" research activities to market, and thus has plans to form strong partnerships with local players. The race in pharma and biotech continues to head East.
Posted by Bruce Lehr April 9, 2010